CARLSBAD, Calif. & STAAD, Switzerland--(BUSINESS WIRE)--Invitrogen (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and Biosynth AG, a manufacturer of specialty chemicals for the life science and pharmaceutical industries, announced the launch of a novel, fluorescence-based culture medium for rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals and medical settings. The new BCM® MRSA ELF® culture media will be manufactured and sold by Biosynth under license from Invitrogen’s Molecular Probes business.
